Clinical bottom line
Low-dose naltrexone (LDN) is an emerging, putative adjunctive treatment for post-traumatic stress disorder (PTSD) in primary care settings. Current evidence is limited and largely preliminary, with no definitive randomized controlled trials specifically evaluating LDN for PTSD. While LDN’s proposed immunomodulatory and neuroinflammatory effects offer a plausible mechanism for symptom amelioration, clinical data remain sparse and inconclusive. Primary care clinicians should consider LDN experimental and investigational for PTSD management, pending rigorous validation. Established PTSD screening and evidence-based therapies remain the cornerstone of care (Magruder et al., 2005; Pagel et al., 2020).
What the evidence shows
PTSD is frequently under-recognized in primary care, with significant barriers to diagnosis and treatment access (Ehlers et al., 2009; Magruder et al., 2005). Screening tools such as the PTSD Checklist have improved case identification but do not address treatment gaps (Piekarski et al., 2019). Conventional PTSD management relies on trauma-focused psychotherapies and pharmacotherapies including selective serotonin reuptake inhibitors (SSRIs) (Pagel et al., 2021).
Low-dose naltrexone, typically dosed at 1–5 mg daily, is hypothesized to exert neuroimmune modulation by transient opioid receptor blockade, potentially reducing neuroinflammation implicated in PTSD pathophysiology (Pagel et al., 2020). However, direct clinical evidence for LDN in PTSD is lacking in the vetted literature. The closest related pharmacologic evidence involves ketamine, which has shown rapid symptom relief in PTSD at higher doses but differs mechanistically and pharmacodynamically from LDN (Day et al., 2025).
No primary care-specific clinical trials or guideline recommendations currently endorse LDN for PTSD. Existing PTSD algorithms emphasize validated psychotherapeutic and pharmacologic approaches (Pagel et al., 2021). Thus, LDN remains a putative candidate warranting formal investigation rather than an established treatment option.
Caveats and uncertainty
The absence of randomized controlled trials or large observational studies evaluating LDN for PTSD limits any definitive conclusions about efficacy or safety. Mechanistic rationale is largely extrapolated from neuroimmune models and anecdotal reports rather than robust clinical data. The heterogeneity of PTSD presentations and comorbidities further complicates assessment of LDN’s potential role.
Potential adverse effects of naltrexone, even at low doses, include gastrointestinal symptoms and possible interference with endogenous opioid signaling, which may affect pain and mood regulation. The long-term safety profile of LDN in PTSD populations is unknown.
Primary care clinicians should be cautious about off-label LDN use for PTSD outside research settings, given the lack of evidence and potential for false hope or diversion from proven therapies. Continued reliance on validated screening and referral pathways remains essential (Magruder et al., 2005; Ehlers et al., 2009).
How this may change practice
Pending rigorous clinical trials, LDN should be considered an experimental, hypothesis-generating candidate for PTSD management rather than a standard treatment. Primary care providers should prioritize established screening tools and evidence-based psychotherapies or pharmacotherapies.
Clinicians may encounter patient interest in LDN due to anecdotal reports or online information. Clear communication about the current lack of validated evidence and the importance of conventional PTSD management is critical.
Future research could clarify whether LDN’s immunomodulatory effects translate into clinical benefit, potentially expanding therapeutic options for PTSD in primary care. Until then, LDN use should be confined to clinical trials or specialist settings with appropriate monitoring.